|
1
|
Raman M, Chen W and Cobb MH: Differential
regulation and properties of MAPKs. Oncogene. 26:3100–3112.
2007.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Brunet A, Roux D, Lenormand P, Dowd S,
Keyse S and Pouysségur J: Nuclear translocation of p42/p44
mitogen-activated protein kinase is required for growth
factor-induced gene expression and cell cycle entry. EMBO J.
18:664–674. 1999.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Roberts PJ and Der CJ: Targeting the
Raf-MEK-ERK mitogen-activated protein kinase cascade for the
treatment of cancer. Oncogene. 26:3291–3310. 2007.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Downward J: Targeting RAS signalling
pathways in cancer therapy. Nat Rev Cancer. 3:11–22.
2003.PubMed/NCBI View
Article : Google Scholar
|
|
5
|
Corcoran RB, Ebi H, Turke AB, Coffee EM,
Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D,
Hung KE, et al: EGFR-mediated re-activation of MAPK signaling
contributes to insensitivity of BRAF mutant colorectal cancers to
RAF inhibition with vemurafenib. Cancer Discov. 2:227–235.
2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Misale S, Yaeger R, Hobor S, Scala E,
Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M,
Siravegna G, et al: Emergence of KRAS mutations and acquired
resistance to anti-EGFR therapy in colorectal cancer. Nature.
28:532–536. 2012.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Vakana E, Pratt S, Blosser W, Dowless M,
Simpson N, Yuan XJ, Jaken S, Manro J, Stephens J, Zhang Y, et al:
LY3009120, a pan RAF inhibitor, has significant anti-tumor activity
in BRAF and KRAS mutant preclinical models of colorectal cancer.
Oncotarget. 8:9251–9266. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Therrien M, Michaud NR, Rubin GM and
Morrison DK: KSR modulates signal propagation within the MAPK
cascade. Gene Dev. 10:2684–2695. 1996.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kortum RL and Lewis RE: The molecular
scaffold KSR1 regulates the proliferative and oncogenic potential
of cells. Mol Cell Biol. 24:4407–4416. 2004.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Razidlo GL, Kortum RL, Haferbier JL and
Lewis RE: Phosphorylation regulates KSR1 stability, ERK activation,
and cell proliferation. J Biol Chem. 279:47808–47814.
2004.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Wang L, Jiang CF, Li DM, Ge X, Shi ZM, Li
CY, Liu X, Yin Y, Zhen L, Liu LZ and Jiang BH: MicroRNA-497
inhibits tumor growth and increases chemosensitivity to
5-fluorouracil treatment by targeting KSR1. Oncotarget.
7:2660–2671. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zhou L, Lyons-Rimmer J, Ammoun S, Muller
J, Lasonder E, Sharma V, Ercolano E, Hilton D, Taiwo I, Barczyk M
and Hanemann CO: The scaffold protein KSR1, a novel therapeutic
target for the treatment of merlin-deficient tumors. Oncogene.
35:3443–3453. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Posch C, Moslehi H, Feeney L, Green GA,
Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T,
et al: Combined targeting of MEK and PI3K/mTOR effector pathways is
necessary to effectively inhibit NRAS mutant melanoma in vitro and
in vivo. Proc Natl Acad Sci USA. 110:4015–4020. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Mendoza MC, Er EE and Blenis J: The
Ras-ERK and PI3K-mTOR pathways: Cross-talk and compensation. Trends
Biochem Sci. 36:320–328. 2011.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Schult C, Dahlhaus M, Ruck S, Sawitzky M,
Amoroso F, Lange S, Etro D, Glass A, Fuellen G, Boldt S, et al: The
multikinase inhibitor Sorafenib displays significant
antiproliferative effects and induces apoptosis via caspase 3, 7
and PARP in B- and T-lymphoblastic cells. BMC Cancer.
10(560)2010.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Coloff JL, Mason EF, Altman BJ, Gerriets
VA, Liu T, Nichols AN, Zhao Y, Wofford JA, Jacobs SR, Ilkayeva O,
et al: Akt requires glucose metabolism to suppress puma expression
and prevent apoptosis of leukemic T cells. J Biol Chem.
286:5921–5933. 2011.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Huang Y, Wu S, Zhang Y, Wang L and Guo Y:
Antitumor effect of triptolide in T-cell lymphoblastic lymphoma by
inhibiting cell viability, invasion, and epithelial-mesenchymal
transition via regulating the PI3K/AKT/mTOR pathway. Onco Targets
Ther. 11:769–779. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Kiessling MK, Curioni-Fontecedro A,
Samaras P, Atrott K, Cosin-Roger J, Lang S, Scharl M and Rogler G:
Mutant HRAS as novel target for MEK and mTOR inhibitors.
Oncotarget. 6:42183–42196. 2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Rodriguez-Viciana P, Warne PH, Dhand R,
Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD and Downward J:
Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature.
370:527–532. 1994.PubMed/NCBI View
Article : Google Scholar
|
|
20
|
Diaz-Flores E and Shannon K: Targeting
oncogenic ras. Gene Dev. 21:1989–1992. 2007.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Li S, Ku CY, Farmer AA, Cong YS, Chen CF
and Lee WH: Identification of a novel cytoplasmic protein that
specifically binds to nuclear localization signal motifs. J Biol
Chem. 273:6183–6189. 1998.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Asada M, Ohmi K, Delia D, Enosawa S,
Suzuki S, You A, Suzuki H and Mizutani S: Brap2 functions as a
cytoplasmic retention protein for p21 during monocyte
differentiation. Mol Cell Biol. 24:8236–8243. 2004.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Takashima O, Tsuruta F, Kigoshi Y,
Nakamura S, Kim J, Katoh MC, Fukuda T, Irie K and Chiba T: Brap2
regulates temporal control of NF-κB localization mediated by
inflammatory response. PLoS One. 8(e58911)2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Ozaki K, Sato H, Inoue K, Tsunoda T,
Sakata Y, Mizuno H, Lin TH, Miyamoto Y, Aoki A, Onouchi Y, et al:
SNPs in BRAP associated with risk of myocardial infarction in Asian
populations. Nat Genet. 41:329–333. 2009.PubMed/NCBI View
Article : Google Scholar
|
|
25
|
Liao YC, Wang YS, Guo YC, Ozaki K, Tanaka
T, Lin HF, Chang MH, Chen KC, Yu ML, Sheu SH and Juo SH: BRAP
activates inflammatory cascades and increases the risk for carotid
atherosclerosis. Mol Med. 17:1065–1074. 2011.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Matheny SA, Chen C, Kortum RL, Razidlo GL,
Lewis RE and White MA: Ras regulates assembly of mitogenic
signalling complexes through the effector protein IMP. Nature.
427:256–260. 2004.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Fatima S, Wagstaff KM, Loveland KL and
Jans DA: Interactome of the negative regulator of nuclear import
BRCA1-binding protein 2. Sci Rep. 5(9459)2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Gao T, Furnari F and Newton AC: PHLPP: A
phosphatase that directly dephosphorylates Akt, promotes apoptosis,
and suppresses tumor growth. Mol Cell. 18:13–24. 2005.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Brognard J, Sierecki E, Gao T and Newton
AC: PHLPP and a second isoform, PHLPP2, differentially attenuate
the amplitude of Akt signaling by regulating distinct Akt isoforms.
Mol Cell. 25:917–931. 2007.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Ran FA, Hsu PD, Wright J, Agarwala V,
Scott DA and Zhang F: Genome engineering using the CRISPR-Cas9
system. Nat Protoc. 11:2281–2308. 2013.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Lanctot AA, Guo Y, Le Y, Edens BM,
Nowakowski RS and Feng Y: Loss of brap results in premature G1/S
phase transition and impeded neural progenitor differentiation.
Cell Rep. 20:1148–1160. 2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Shi L, Weng XQ, Sheng Y, Wu J, Ding M and
Cai X: Staurosporine enhances ATRA-induced granulocytic
differentiation in human leukemia U937 cells via the MEK/ERK
signaling pathway. Oncol Rep. 36:3072–3080. 2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Liu AH, Cao YN, Liu HT, Zhang WW, Liu Y,
Shi TW, Jia GL and Wang XM: DIDS attenuates staurosporine-induced
cardiomyocyte apoptosis by PI3K/Akt signaling pathway: Activation
of eNOS/NO and inhibition of Bax translocation. Cell Physiol
Biochem. 22:177–186. 2008.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Darzynkiewicz Z, Bruno S, Del Bino G,
Gorczyca W, Hotz MA, Lassota P and Traganos F: Features of
apoptotic cells measured by flow cytometry. Cytometry. 13:795–808.
1992.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Bedner E, Li X, Gorczyca W, Melamed MR and
Darzynkiewicz Z: Analysis of apoptosis by laser scanning cytometry.
Cytometry. 35:181–195. 1999.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Cohen GM: Caspase: The executioners of
apoptosis. Biochem J. 326:1–16. 1997.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Koon JC and Kubiseski TJ: Developmental
arrest of caenorhabditis elegans BRAP-2 mutant oxidative stress is
dependent on BRC-1. J Biol Chem. 285:13437–13443. 2010.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Wang B, Cao C, Liu X, He X, Zhuang H, Wang
D and Chen B: BRCA1-associated protein inhibits glioma cell
proliferation and migration and glioma stem cell self-renewal via
the TGF-β/PI3K/AKT/mTOR signalling pathway. Cell Oncol (Dordr).
43:223–235. 2020.PubMed/NCBI View Article : Google Scholar
|
|
39
|
D'Amora DR, Hu Q, Pizzardi M and Kubiseski
TJ: BRAP-2 promotes DNA damage induced germline apoptosis in C.
elegans through the regulation of SKN-1 and AKT-1. Cell Death
Differ. 25:1276–1288. 2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Rajakulendran T, Sahmi M, Lefraancois M,
Sicheri F and Therrien M: A dimerization-dependent mechanism drives
RAF catalytic activation. Nature. 461:542–545. 2009.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Peng SB, Henry JR, Kaufman MD, Lu WP,
Smith BD, Vogeti S, Rutkoski TJ, Wise S, Chun L, Zhang Y, et al:
Inhibition of RAF isoforms and active dimers by LY3009120 leads to
anti-tumor activities in RAS or BRAF mutant cancers. Cancer Cell.
28:384–398. 2015.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Zhao WL: Targeted therapy in T-cell
malignancies: Dysregulation of the cellular signaling pathways.
Leukemia. 24:13–21. 2010.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Xu Z, Stokoe D, Kane LP and Weiss A: The
inducible expression of the tumor suppressor gene PTEN promotes
apoptosis and decreases cell size by inhibiting the PI3K/Akt
pathway in Jurkat T cells. Cell Growth Differ. 13:285–296.
2002.PubMed/NCBI
|
|
44
|
Wang Z, Gjörloff-Wingren A, Saxena M,
Pathan N, Reed JC and Mustelin T: The tumor suppressor PTEN
regulates T cell survival and antigen receptor signaling by acting
as a phosphatidylinositol 3-phosphatase. J Immunol. 164:1934–1939.
2000.PubMed/NCBI View Article : Google Scholar
|
